In Silico Analysis of Bacteriocins from Lactic Acid Bacteria Against SARS‑CoV‑2

Erol I., Kotil E., Fidan Ö. , Yetiman A. E. , Durdagi S., Ortakcı F.

PROBIOTICS AND ANTIMICROBIAL PROTEINS, vol.0, no.0, pp.1-13, 2021 (Journal Indexed in SCI Expanded)

  • Publication Type: Article / Article
  • Volume: 0 Issue: 0
  • Publication Date: 2021
  • Doi Number: 10.1007/s12602-021-09879
  • Page Numbers: pp.1-13


The COVID-19 pandemic caused by a novel coronavirus (SARS-CoV-2) is a serious health concern in the twenty-frst century for scientists, health workers, and all humans. The absence of specifc biotherapeutics requires new strategies to prevent the spread and prophylaxis of the novel virus and its variants. The SARS-CoV-2 virus shows pathogenesis by entering the host cells via spike protein and Angiotensin-Converting Enzyme 2 receptor protein. Thus, the present study aims to compute the binding energies between a wide range of bacteriocins with receptor-binding domain (RBD) on spike proteins of wild type (WT) and beta variant (lineage B.1.351). Molecular docking analyses were performed to evaluate binding energies. Upon achieving the best bio-peptides with the highest docking scores, further molecular dynamics (MD) simulations were performed to validate the structure and interaction stability. Protein–protein docking of the chosen 22 biopeptides with WT-RBD showed docking scores lower than−7.9 kcal/mol. Pediocin PA-1 and salivaricin P showed the lowest (best) docking scores of−12 kcal/mol. Pediocin PA-1, salivaricin B, and salivaricin P showed a remarkable increase in the double mutant’s predicted binding afnity with−13.8 kcal/mol,−13.0 kcal/mol, and−12.5 kcal/mol, respectively. Also, a better predicted binding afnity of pediocin PA-1 and salivaricin B against triple mutant was observed compared to the WT. Thus, pediocin PA-1 binds stronger to mutants of the RBD, particularly to double and triple mutants. Salivaricin B showed a better predicted binding afnity towards triple mutant compared to WT, showing that it might be another bacteriocin with potential activity against the SARS-CoV-2 beta variant. Overall, pediocin PA-1, salivaricin P, and salivaricin B are the most promising candidates for inhibiting SARS-CoV-2 (including lineage B.1.351) entrance into the human cells. These bacteriocins derived from lactic acid bacteria hold promising potential for paving an alternative way for treatment and prophylaxis of WT and beta variants.